📰 Michael Raab News
Michael Raab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Raab. Real-time updates on events, politics, business and more.
July 16, 2024
Margin. The result is seen as pivotal for the future ties of the nation with the European Union. And u. S. Banks are braced for the worth order since the quarter for the worse quarter since the financial crisis. Jp morgan kicks off a big rank week. Good morning, it is 6 00 a. M. In london. It is getting hot here. With an untamed virus irrationalional exuberance in stocks. It could get tricky. Goldman has upped their view of their earnings. Yall so have the gilead story in terms of remdesivir hel...
June 3, 2024
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 33,040,000 shares, a drop of 6.1% from the April 30th total of 35,170,000 shares. Based on an average daily trading volume, of 5,610,000 shares, […]
June 1, 2024
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 7,500 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $6.72, for a total transaction of $50,400.00. Following the sale, the chief executive officer now owns 1,270,273 shares in the company, valued […]
May 28, 2024
Piper Sandler reissued their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday morning, Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock. ARDX has been the topic of a number of other research reports. SVB Leerink began coverage on shares of […]
May 28, 2024
Wedbush reissued their outperform rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report published on Friday, Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ARDX. Citigroup increased their target price on shares of Ardelyx from […]
May 27, 2024
Piper Sandler restated their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the company. StockNews.com cut Ardelyx from a hold […]
May 25, 2024
StockNews.com downgraded shares of Ardelyx (NASDAQ:ARDX – Free Report) from a hold rating to a sell rating in a report published on Tuesday. A number of other equities analysts also recently issued reports on the company. SVB Leerink started coverage on Ardelyx in a report on Friday, April 5th. They issued an outperform rating and […]
May 22, 2024
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
May 16, 2024
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 3,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $7.99, for a total value of $23,970.00. Following the transaction, the chief executive officer now owns 1,307,933 shares in the company, […]
May 16, 2024
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 3,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $7.99, for a total value of $23,970.00. Following the sale, the chief executive officer now directly owns 1,307,933 shares in the company, […]